Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. The company specializes in diabetes care and biopharmaceuticals, offering a range of products that include insulin, GLP-1 receptor agonists, and hemophilia treatments.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| NOVOB 0.58% 2029-06-11 CHFNovo Nordisk | Denmark | 2029-06-11 | 0.575 | 0.62 |
| NOVOB 0.94% 2032-06-11 CHFNovo Nordisk | Denmark | 2032-06-11 | 0.943 | 0.97 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Novo Nordisk has a strong presence in the bond market, issuing its first bonds in the late 1990s as part of its strategy to finance expansion and research initiatives. Notably, in 2021, the company issued €1 billion in green bonds to support sustainable projects aligned with its environmental goals, reflecting a growing trend in socially responsible investing. Currently, Novo Nordisk's bond yields are competitive compared to the pharmaceutical industry, with favorable ratings from major agencies, indicating solid credit quality and financial stability.